Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) SEC filings page provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, quarterly and annual reports, and other filings that describe material agreements, financial results, and key developments in Ultragenyx’s rare disease business.
Form 8-K filings for Ultragenyx often cover topics such as royalty purchase agreements, clinical and regulatory milestones, and financial updates. For example, the company has reported a Royalty Purchase Agreement with an OMERS investment vehicle involving a portion of future Crysvita royalty payments in the United States and Canada, including details on purchase price, royalty percentages, and caps based on multiples of the purchase price. Other 8-Ks summarize press releases announcing quarterly financial results, revenue by product, operating expenses, and net loss.
Ultragenyx also uses Form 8-K to report clinical and regulatory events, including initiation and progress of rolling Biologics License Application submissions for DTX401 in glycogen storage disease type Ia, longer-term Phase 3 data for DTX401, Breakthrough Therapy Designation for GTX-102 in Angelman syndrome, enrollment status of the Phase 3 Aspire study, and FDA communications such as a Complete Response Letter for UX111 in Sanfilippo syndrome type A. These filings outline requested chemistry, manufacturing, and controls information and the company’s plans to address regulatory feedback.
Through Stock Titan, users can review Ultragenyx’s SEC filings and benefit from AI-powered summaries that explain the significance of complex documents, including 10-K and 10-Q reports when available, as well as Form 4 insider transaction reports. Real-time updates from EDGAR combined with AI-generated insights help readers understand how material agreements, clinical data, and regulatory interactions influence Ultragenyx’s operations and capital structure in the rare and ultra-rare genetic disease space.
Ultragenyx Pharmaceutical Inc. executive Eric Crombez, EVP and Chief Medical Officer, sold 344 shares of common stock at $24.96 per share on May 5, 2026. According to the footnotes, these shares were sold to pay required tax withholdings related to the vesting of restricted stock units (RSUs). After this tax-related sale, Crombez directly holds 111,189 shares of Ultragenyx common stock.
Ultragenyx Pharmaceutical Inc. reported a net loss of $185 million for the quarter ended March 31, 2026, on $136 million in total revenues, down 2% year over year. Product sales were $89 million, led by Crysvita at $46 million, while Crysvita royalty revenue contributed $47 million.
Research and development expenses rose to $187 million, driven by manufacturing and late-stage work on gene therapies DTX401 and UX111 and biologic programs GTX‑102 and UX143. Selling, general and administrative costs were stable at $88 million.
The company booked $30 million of restructuring charges tied to a February 2026 plan that cut its workforce by about 10% and curtailed certain activities, including UX143 manufacturing. Cash, cash equivalents and marketable securities totaled $534 million, while liabilities for sales of future Crysvita royalties reached $1.2 billion.
Ultragenyx Pharmaceutical reported first quarter 2026 revenue of $136 million, slightly below $139 million a year earlier, with Crysvita contributing $93 million, Dojolvi $18 million, Evkeeza $18 million and Mepsevii $7 million. Product sales were $89 million and royalty revenue $47 million.
The company posted a net loss of $185 million, or $1.84 per share, compared with a $151 million loss, or $1.57 per share, in 2025 as total operating expenses rose to $305 million. Cash, cash equivalents and marketable securities were $534 million as of March 31, 2026, down from $737 million at year-end, with $197 million of net cash used in operations.
Ultragenyx reaffirmed its 2026 guidance, targeting total revenue of $730–$760 million and combined R&D and SG&A expenses flat to slightly down versus 2025, and continues to aim for profitability in 2027. The company highlighted two gene therapy BLAs under FDA Priority Review for DTX401 and UX111, with PDUFA action dates on August 23, 2026 and September 19, 2026, respectively, and positive longer-term data from the GTX-102 Angelman syndrome program ahead of a Phase 3 readout in the second half of 2026.
Ultragenyx Pharmaceutical Inc.’s Chief Financial Officer Howard Horn reported an open-market sale of 4,683 shares of common stock at $24.90 per share. After this transaction, he directly owns 110,342 shares, which the disclosure notes include shares underlying RSUs that are subject to vesting conditions.
Form 144 notice for proposed sales of Common Stock by an affiliate. The filing lists awarded restricted stock and performance shares with grant/vesting dates and quantities: 1,743, 1,343, 939, and 658 shares tied to dates between 10/09/2024 and 03/01/2026. The filing also records multiple reported sales by Howard Horn during the prior three months, including transactions on 02/02/2026, 03/02/2026, 03/03/2026, and 04/01/2026 with per‑trade share counts of 3,061, 5,290, 3,119, 1,635, and 4,683.
Ultragenyx Pharmaceutical Inc reports a passive institutional holding disclosure. Vanguard Portfolio Management reported beneficial ownership of 5,410,208 shares of Common Stock, representing 5.50% of the class as of 03/31/2026. The filing lists 24,216 shares of sole voting power and sole dispositive power over 5,410,208 shares. The filing is signed by Vanguard's Head of Global Fund Administration on 04/29/2026.
Ultragenyx Pharmaceutical Inc. reported that SVP and Chief Accounting Officer Theodore Alan Huizenga received an equity compensation grant. He was awarded 20,241 shares of common stock in the form of restricted stock units, increasing his direct holdings to 68,911 shares. These RSUs vest in four equal annual installments on each anniversary of the grant date, becoming fully vested after four years.
He also received a stock option for 7,348 shares of common stock with an exercise price of $24.61 per share, expiring on April 22, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments thereafter.
Ultragenyx Pharmaceutical Inc. President & CEO Emil D. Kakkis reported new equity compensation awards and updated indirect holdings. He received 76,745 Restricted Stock Units (RSUs) under the company’s 2023 Incentive Plan, which vest in four equal annual installments from the grant date.
He was also granted a stock option for 132,693 shares of common stock at an exercise price of $24.52 per share, vesting 25% on the first anniversary of the grant and the remainder monthly thereafter until 2036-04-16. Following these awards, he directly holds 735,739 shares of common stock.
The filing also reflects updated indirect ownership, including 1,758,985 shares held through the Emil Kakkis and Jenny Soriano Living Trust and an aggregate 400,000 shares contributed to two grantor retained annuity trusts (GRATs). These changes reflect compensation grants and estate-planning transfers rather than open-market trades.
Ultragenyx Pharmaceutical Inc. reported that officer Dennis Karl Huang received equity awards consisting of common stock and stock options. He was granted 23,116 shares of common stock as Restricted Stock Units (RSUs), bringing his direct common stock holdings to 147,845 shares after the award.
The RSUs were granted under the company’s 2023 Incentive Plan and vest in four equal annual installments on each anniversary of the grant date. Huang was also granted 79,936 stock options with an exercise price of $24.52 per share, expiring on April 16, 2036, which vest over four years with 1/4 vesting after one year and the remainder vesting monthly.
Ultragenyx Pharmaceutical Inc. executive John Richard Pinion received new equity awards in the form of restricted stock units and stock options. He was granted 23,116 shares of common stock as RSUs under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 133,142 shares after the award. These RSUs vest in four equal annual installments on each anniversary of the grant date.
He also received a stock option covering 79,936 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following three years.